Johnson & Johnson to buy Alios BioPharma
Johnson & Johnson (NYSE: JNJ – $104.58) announced a definitive agreement to acquire Alios BioPharma, Inc. for about $1.75 billion in cash. Alios, a privately-held, clinical stage biopharmaceutical company located in South San Francisco, is developing a portfolio of potential therapeutics and screening systems for viral infections including respiratory syncytial virus, influenza, rhinovirus and Hepatitis C. The acquisition will include Alios BioPharma’s compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus. Alios’ pipeline is closely aligned with J&J’s Janssen Pharmaceutical subsidiary’s other anti-viral offerings and makes for a nice fit. The shares of JNJ have settled back of late along with the overall market, but I still think a position in this diversified healthcare giant would be a solid holding to almost any conservative income portfolio with a below-median beta of .70 and an above average dividend yielding 2.6%.